Hobson Prior’s Post

CRISPR/Cas9 Prime Editing pushes the boundaries of precision and safety in gene editing. By utilizing a modified Cas9 (nCas9) and a guide RNA fused with a reverse transcriptase, researchers can now introduce highly specific and complex mutations—without creating double-strand breaks. This innovative approach offers a safer alternative to traditional CRISPR methods, particularly in therapeutic applications, and opens new doors for studying and treating genetic diseases. 🌱 Applications range from correcting genetic mutations and creating disease models to engineering cells for synthetic biology applications like biofuel production. Despite some challenges, including edit size limitations and delivery methods, Prime Editing has the potential to revolutionize biotechnology and medicine. Let’s keep an eye on the exciting future of gene editing! #CRISPR #PrimeEditing #Biotech #GeneTherapy #SyntheticBiology #GeneticEngineering https://lnkd.in/e_wEY5FZ

🚀🔬 Unleashing New Frontiers in Gene Editing through L-PGI Technology! 🔬🚀 A huge congratulations to the visionary team at Tome Biosciences for their paper, "Ligase-mediated programmable genomic integration (L-PGI): an efficient site-specific gene editing system that overcomes the limitations of reverse transcriptase-based editing systems." Summary and Outlook 💡 L-PGI introduces a unique gene editing strategy, using ligase-mediated techniques to overcome the limitations of traditional reverse transcriptase-based systems. By optimizing nCas9 nicking and using synthetic DNA, L-PGI achieves a variety of edits, including point mutations and larger insertions, with superior precision in nondividing cells and in vivo models. This work highlights L-PGI's potential to transform treatments for genetic disorders, offering a scalable and precise approach for therapeutic gene editing. With a focus on efficiency and reduced off-target effects, L-PGI promises to be a game-changer in the field. ALC-0315, provided by BroadPharm, played an essential role in the lipid nanoparticle formulations, enabling efficient delivery of L-PGI components for successful gene editing. This contribution underscores the importance of high-quality reagents in achieving superior therapeutic outcomes. 🌐 Check the full publication here: https://lnkd.in/gCDY9__S   Ready to take your gene editing research to the next level? Explore ALC-0315, its analogs, and other ionizable lipids like LP01, ideal for delivering CRISPR/Cas9 components to achieve precise genome editing in vivo:  🔗 ALC-0315 & analogs —> https://lnkd.in/gyxkK5bX  🔗 LP01 & analogs —> https://lnkd.in/gcad8isj  🔗 Other ionizable lipids —> https://lnkd.in/gZ9DSvGf #Research #RNA #mRNA #LNP #DrugDelivery #Vaccine #CovidVaccine #Lipid #IonizableLipid #CationicLipid #BranchedLipid #Phospholipid #Sphingolipid #Cholesterol #PEGLipid #SM102 #ALC0315 

Just came across an interesting article explaining CRISPR in a really easy-to-understand way! If you're curious about how this revolutionary gene-editing technology works and where it comes from, this is a must-read. It covers everything from the basics of CRISPR to its potential applications in medicine and beyond. Synthego Corporation CRISPR Therapeutics CRISPR Medicine News Biotech Gene Solutions Gene Editing Frontiers LLC Ambry Genetics MIT Technology Review Medicine Biotech Biotechnology Innovation Organization Twist Bioscience Bio-Rad Laboratories Biophys Ltd Applied BioPhysics, Inc. CRISPR CRISPR QC #CRISPR #Genetics #Biotech #ScienceForEveryone #Innovation #GeneEditing #Medicine

AI-Powered Analysis for Gene Editing with CRISPR: Unlocking New Frontiers in Biotechnology Transforming Gene Editing with AI AI is revolutionizing CRISPR gene editing by addressing challenges in precision, efficiency, and scalability. Here’s how: 1️⃣ Enhanced Target Identification AI algorithms analyze genomic data to pinpoint the most effective and least risky gene targets. This reduces off-target effects and ensures higher accuracy in editing, making CRISPR applications safer. 2️⃣ Optimized Guide RNA Design CRISPR relies on guide RNAs to locate specific DNA sequences. AI streamlines the design process, identifying the best sequences for maximum efficiency and minimal errors. 3️⃣ Predicting Outcomes AI models simulate gene edits, predicting their potential outcomes and impact. This enables researchers to foresee unintended consequences, accelerating research while reducing trial-and-error experimentation. 4️⃣ Accelerating Drug Development AI-driven CRISPR analysis helps identify genetic links to diseases faster, enabling the development of gene-based therapies. This is particularly promising for rare genetic disorders and personalized medicine. #CRISPR #GeneEditing #AIInBiotech #Genomics #PrecisionMedicine #Biotechnology #AIApplications #FutureOfHealthcare #ResearchInnovation #BiotechBreakthroughs #AIforeveryone #AIforeveryonecourses

🔬 Discovering Precision in Gene Editing: A Leap Forward with BreakTag 🔬 Gene editing is getting a precision upgrade! The new BreakTag method, recently featured in Nature Biotechnology, enhances our understanding of CRISPR-Cas9 induced breaks—paving the way for more accurate and safe genetic modifications. This groundbreaking approach could significantly advance therapeutic applications, making gene therapy safer and more effective. Dive into the details of how about 35% of DNA breaks are staggered and what this means for future treatments. ✨ 👉 Stay tuned for how this innovation could change the face of medicine and genetic research! 🔗 https://lnkd.in/exCNPPA6 #CRISPR #GeneEditing #Innovation #ScienceNews #Biotechnology #Nature

CRISPR/Cas genome editing in plants: mechanisms, applications, and overcoming bottlenecks‼️ Abstract The CRISPR/Cas systems have emerged as transformative tools for precisely manipulating plant genomes and enhancement. It has provided unparalleled applications from modifying the plant genomes to resistant enhancement. This review manuscript summarises the mechanism, application, and current challenges in the CRISPR/Cas genome editing technology. It addresses the molecular mechanisms of different Cas genes, elucidating their applications in various plants through crop improvement, disease resistance, and trait improvement. The advent of the CRISPR/Cas systems has enabled researchers to precisely modify plant genomes through gene knockouts, knock-ins, and gene expression modulation. Despite these successes, the CRISPR/Cas technology faces challenges, including off-target effects, Cas toxicity, and efficiency. In this manuscript, we also discuss these challenges and outline ongoing strategies employed to overcome these challenges, including the development of novel CRISPR/Cas variants with improved specificity and specific delivery methods for different plant species. The manuscript will conclude by addressing the future perspectives of the CRISPR/Cas technology in plants. Although this review manuscript is not conclusive, it aims to provide immense insights into the current state and future potential of CRISPR/Cas in sustainable and secure plant production.

New #AI method, #LINGER, cracks the code on gene regulation! 💡 LINGER, developed by Clemson University scientists, infers gene regulatory networks from single-cell multiomics data by integrating atlas-scale bulk data and prior knowledge. It outperforms existing methods and enables interpreting disease variants from expression data alone. Quick Read: https://lnkd.in/gYViayW2 #bioinformatics #genomics #machinelearning #generegulation #bigdata #sciencenews #biotechnology

CRISPR gene editing is revolutionising healthcare and biotechnology, offering the ability to treat inherited diseases, fight cancer, and develop resilient crops. However, recent research reveals that promising tools like AZD7648, while improving precision through homology-directed repair, may introduce massive unintended genomic changes including DNA deletions and chromosome breaks. This highlights a critical need for secure, precise, and predictable gene editing workflows to ensure patient safety and genome stability. At Zortrex, we believe this challenge can be solved. By integrating our Tokenized Quantum Cognitive Exchange Platform (TQCEP) into genomic research: ✅ We can secure genetic data end-to-end with quantum-grade tokenization. ✅ Enable tokenized simulations to predict and prevent unintended edits. ✅ Facilitate global collaboration without compromising data integrity. Precision medicine and biotechnology cannot afford guesswork. The time for quantum-secure, scalable solutions is now. If you're in healthcare, biotech, or genetic research, contact us today to explore how TQCEP can help secure and accelerate your breakthroughs. https://lnkd.in/e3an6R-p #CRISPR #GenomeEditing #HealthcareInnovation #QuantumSecurity #PrecisionMedicine #Biotechnology #QuantumTechnology #DataSecurity #GeneTherapy #FutureOfHealthcare

Gene&Cell Therapy >> Scientists and startups reveal new gene insertion techniques, though much remains behind closed doors: #ASGCT24: Several secretive and well-funded biotechs are sharing the first glimpses of data from a new suite of gene editing tools that promise to overcome one of the field’s grand challenges: precisely inserting large sequences of DNA, or even whole genes, into the genome. So far, most work with CRISPR gene editing has used the tool to turn off problematic genes. Newer versions of the technology, like base editing and prime editing, can make small changes to one or a few letters of genetic code, respectively. But replacing large swathes of errant code, or uploading brand new ones, has remained a challenge. ReNAgade Therapeutics, SalioGen Therapeutics and Tome Biosciences have been quietly working on new gene insertion techniques. So has David Liu, a prominent gene editing scientist from the Broad Institute of MIT and Harvard. Those startups and Liu all disclosed new technologies this week at the American Society of Gene & Cell Therapy’s conference in Baltimore. Jason Cole “This is our coming-out party, scientifically,” SalioGen CEO Jason Cole told Endpoints News. His company on Tuesday presented data on its experimental therapy for an inherited form of vision loss called Stargardt disease. In a mouse experiment, the approach restored expression of the gene in 40% of photoreceptors and reduced a harmful byproduct believed to contribute to vision loss by a similar amount. Stargardt disease has been tough to tackle with other approaches. The broken gene is too big to squeeze into the viral vectors commonly used in traditional gene therapies. And since the disease can be caused by a large number of different mutations in that gene, fixing those mutations with existing CRISPR tools is impractical. Gene insertion offers a new solution. SalioGen uses a new lipid nanoparticle to deliver a fresh copy of the gene into the eye, which gets stitched into the genome with an enzyme called a transposase, which is familiar to biologists for moving so-called “jumping genes” throughout the genome. SalioGen is working on a similar approach to treat cystic fibrosis in the lungs, which is also caused by several mutations in a large gene. And it hopes that’s just the start. “These integrating technologies can really open up the number of indications we can go after with genetic medicine,” Cole said. A ‘final chapter in genomic medicine’ Gene insertion is the new vanguard of gene editing. The original three biotechs built around CRISPR gene editing — CRISPR Therapeutics, Editas Medicine and Intellia Therapeutics — have all begun early discovery work on gene insertion technologies. And many small startups are developing their own gene insertion tools. Although adding or replacing entire genes isn’t always… #lucidquest #genetherapy #celltherapy

Check out this new new gene editing technique which uses bacterial "jumping genes" to offer the potential to overcome some limitations of CRISPR: #CRISPR #Biotech #Innovation